stockrowGRAIL, Inc. (GRAL) vs Veracyte, Inc. (VCYT)
- GRAIL, Inc. GRAL 117.27 −1.56%
- Veracyte, Inc. VCYT 24.05 +0.21%
GRAIL, Inc. and Veracyte, Inc. are both Diagnostics & Research companies. GRAIL, Inc. is the larger, with a market value of $5.3B against $1.9B — 2.8× the size. GRAIL, Inc. has negative trailing earnings, so its P/E is not meaningful; Veracyte, Inc. trades at 15.2×. Veracyte, Inc. grew revenue faster over the last twelve months: 17.5% against 17.5%. Veracyte, Inc. has the higher net margin (21.8% vs −243.8%) and the higher return on invested capital (4.33% vs −14.7%). Across the 16 metrics below, Veracyte, Inc. leads on 15 and GRAIL, Inc. on 1.
Valuation
Profitability
| Metric | GRAL | VCYT | Diagnostics & Research median |
|---|---|---|---|
| Gross margin | 0.00% | 71.98% | 48.32% |
| Operating margin | (347.28%) | 17.08% | (5.68%) |
| Net margin | (243.80%) | 21.80% | (4.10%) |
| Free cash flow margin | (187.27%) | 27.84% | 0.00% |
| Return on equity | (17.31%) | 9.43% | 0.00% |
| Return on assets | (15.24%) | 8.63% | (6.05%) |
| Return on invested capital | (14.74%) | 4.33% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack